The average fair value estimate for Fractyl Health shifted from about US$60.40 to roughly US$47.83, echoing the sharp reset in Street price targets from US$96 to US$39 and from US$48 to US$5. Analysts are weighing the six month Revita pivotal data against concerns about execution risk, real world uptake and how much of the weight regain benefit is already reflected in the stock. Read on to see how this evolving narrative could shape your view on Fractyl Health over the coming quarters.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Both Canaccord and Craig-Hallum keep Buy ratings on Fractyl Health, which signals that, despite lower targets, they still see a constructive risk reward profile for the stock.
-
Canaccord highlights six month Revita pivotal data, including an LS mean 80% weight loss maintained at six months versus 68% with the sham procedure. The firm views this as supportive of the one time procedure's ability to reduce weight regain after stopping tirzepatide.
-
Craig-Hallum points to statistically significant top line six month data from the pivotal REMAIN-1 cohort, with Revita patients showing a 38% reduction in weight regain relative to sham. The firm sees this as supporting the underlying clinical concept.
🐻 Bearish Takeaways
-
Canaccord cut its Fractyl Health price target from US$96 to US$39, which reflects a reset in expectations and brings valuation assumptions closer to the current pivotal dataset.
-
Craig-Hallum reduced its target from US$48 to US$5 after placebo adjusted results came in below its forecasts, which underscores concern about how much of the weight regain effect and Revita uptake should be built into long term growth assumptions.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 6 risks for Fractyl Health. See which could impact your investment.
How This Changes the Fair Value For Fractyl Health
-
The average fair value estimate for Fractyl Health moved from about US$60.40 to roughly US$47.83.
-
Forecast revenue growth moved to about 293.23%, which is a reset from a very large prior figure.
-
The projected profit margin remained at 12.58%.
-
The future P/E multiple estimate moved from about 741.51x to roughly 144.89x.
-
The discount rate moved from 9.23% to 12.54%.
Never Miss an Update: Follow The Narrative
Narratives link Fractyl Health's clinical story, business model and risk profile to a financial forecast and fair value that update as new information arrives. They help you see how changing data points can affect the bigger picture over time.
Head over to the Simply Wall St Community and follow the Narrative on Fractyl Health to stay up to date on:
-
How Revita and the REMAIN-1 and REVEAL-1 programs could support a procedure based obesity and diabetes business that uses existing endoscopy infrastructure and high volume centers.
-
What the German real world registry data implies for the durability of weight loss and HbA1c control and how the Rejuva Smart GLP-1 platform could become a second pillar alongside Revita.
-
Key risks around delisting pressure, finite cash runway into early 2027, regulatory and reimbursement uncertainty and the possibility that broader obesity populations respond differently to Revita than early trials suggest.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GUTS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
